Skip to main content

IDENTIDAD, TOPOLOGIA Y GEOMETRIA DE LOS DOMINIOS DE SEÑALIZACION DEL TCR EN RESPUESTAS INMUNES PROTECTORAS, TERAPEUTICAS E AUTO-INMUNES

PID2019-104703GB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Modulating T Cell Responses by Targeting CD3

  • Menon, Ashwathi Puravankara
  • Moreno, Beatriz
  • Meraviglia-Crivelli, Daniel
  • Nonatelli, Francesca
  • Villanueva, Helena
  • Barainka, Martin
  • Zheleva, Angelina
  • Santen, Hisse M. van
  • Pastor, Fernando
Harnessing the immune system to fight cancer has become a reality with the clinical success of immune-checkpoint blockade (ICB) antibodies against PD(L)-1 and CTLA-4. However, not all cancer patients respond to ICB. Thus, there is a need to modulate the immune system through alternative strategies for improving clinical responses to ICB. The CD3-T cell receptor (TCR) is the canonical receptor complex on T cells. It provides the "first signal" that initiates T cell activation and determines the specificity of the immune response. The TCR confers the binding specificity whilst the CD3 subunits facilitate signal transduction necessary for T cell activation. While the mechanisms through which antigen sensing and signal transduction occur in the CD3-TCR complex are still under debate, recent revelations regarding the intricate 3D structure of the CD3-TCR complex might open the possibility of modulating its activity by designing targeted drugs and tools, including aptamers. In this review, we summarize the basis of CD3-TCR complex assembly and survey the clinical and preclinical therapeutic tools available to modulate CD3-TCR function for potentiating cancer immunotherapy., Instituto Salud Carlos III financed with Feder Funds PI20-01132 (“A way to make Europe”) for F.P. PID2019-104703GB-I00/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation (MICINN) for H.M.v.S. This project has received funding from the European Union Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 721358 and under the H2020-FETOPEN “DESTINATION” grant agreement no. 899833., Peer reviewed